• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

眼内手术后急性眼内炎中辅助性皮质类固醇治疗与单独使用抗生素的比较。

Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure.

机构信息

Stein Eye Institute, UCLA, Los Angeles, California, USA.

出版信息

Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD012131. doi: 10.1002/14651858.CD012131.pub3.

DOI:10.1002/14651858.CD012131.pub3
PMID:35665485
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9169535/
Abstract

BACKGROUND

Endophthalmitis refers to severe infection within the eye that involves the aqueous humor or vitreous humor, or both, and that threatens vision. Most cases of endophthalmitis are exogenous (i.e. due to inoculation of organisms from an outside source), and most exogenous endophthalmitis is acute and occurs after an intraocular procedure. The mainstay of treatment is emergent administration of broad-spectrum intravitreous antibiotics. Due to their anti-inflammatory effects, steroids in conjunction with antibiotics have been proposed as being beneficial in endophthalmitis management.

OBJECTIVES

To assess the effects of antibiotics combined with steroids versus antibiotics alone for the treatment of acute endophthalmitis following intraocular surgery or intravitreous injection.

SEARCH METHODS

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2021, Issue 8), MEDLINE Ovid (1946 to August 2021), Embase Ovid (1980 to August 2021), LILACS (Latin American and Caribbean Health Sciences Literature database) (1982 to August 2021), the ISRCTN registry; searched August 2021, ClinicalTrials.gov; searched August 2021, and the WHO International Clinical Trials Registry Platform; searched August 2021. We did not use any date or language restrictions in the electronic searches for trials.

SELECTION CRITERIA

We included randomized controlled trials (RCTs) comparing the effectiveness of adjunctive steroids with antibiotics alone in the management of acute, clinically diagnosed endophthalmitis following intraocular surgery or intravitreous injection. We excluded trials with participants with endogenous endophthalmitis unless outcomes were reported by source of infection. We imposed no restrictions on the method or order of administration, dose, frequency, or duration of antibiotics and steroids.

DATA COLLECTION AND ANALYSIS

We used standard Cochrane methodology, and graded the certainty of the body of evidence for six outcomes using the GRADE classification.

MAIN RESULTS

We included four RCTs with a total of 264 eyes of 264 participants in this review update. The studies were conducted in South Africa, India, and the Netherlands. All studies used intravitreous dexamethasone for adjunctive steroid therapy and a combination of two intravitreous antibiotics that provided gram-positive and gram-negative coverage for the antibiotic therapy. We judged two trials to be at overall low risk of bias, and the other two studies to be at overall unclear risk of bias due to lack of reporting of study methods. Only one study was registered in a clinical trial register.  While none of the included studies reported the primary outcome of complete resolution of endophthalmitis as defined in our protocol, one study reported combined anatomical and functional success (i.e. proportion of participants with intraocular pressure of at least 5 mmHg and visual acuity of at least 6/120). Very low certainty evidence suggested no difference in combined success when comparing adjunctive steroid to antibiotics alone (risk ratio (RR) 1.08, 95% confidence interval (CI) 0.80 to 1.45; 32 participants). Low certainty evidence from two studies suggested that adjunctive dexamethasone may result in having a good visual outcome (Snellen visual acuity 6/6 to 6/18) at 3 months compared with antibiotics alone (RR 1.95, 95% CI 1.05 to 3.60; 60 participants); however, the evidence was less conclusive at 12 months (RR 1.12, 95% CI 0.92 to 1.37; 2 studies; 195 participants; low certainty evidence). Investigators of one study reported improvement in visual acuity, but we could not estimate the effect of adjunctive steroid therapy because the study investigators did not provide any estimates of precision. Only one study examined intraocular pressure (IOP). The evidence suggests that adjunctive dexamethasone may reduce IOP slightly after 12 months of interventions (mean difference -1.90, 95% CI -3.78 to 0.07; 1 study; 167 participants; low certainty evidence). Three studies reported adverse events (retinal detachment, hypotony, proliferative vitreoretinopathy, seclusion of pupil, floaters, and pucker). The total numbers of adverse events were 14 out of 111 (12.6%) for those who received dexamethasone versus 12 out of 116 (10.3%) for those who did not. We could only perform a pooled analysis for the occurrence of retinal detachment: any difference between the two treatment groups was uncertain (RR 1.41, 95% CI 0.53 to 3.74; 227 participants; low certainty evidence). No study reported cost-related outcomes.

AUTHORS' CONCLUSIONS: The currently available evidence on the effectiveness of adjunctive steroid therapy versus antibiotics alone in the management of acute endophthalmitis after intraocular surgery is inadequate. We found no studies that had enrolled cases of acute endophthalmitis following intravitreous injection. A combined analysis of two studies suggests that use of adjunctive steroids may provide a higher chance of having a good visual outcome at three months than not using adjunctive steroids. However, considering that most of the confidence intervals crossed the null, and that this review was limited in scope and applicability to clinical practice, it is not possible to conclude whether the use of adjunctive steroids is effective at this time. Any future trials should examine whether adjunctive steroids may be useful in certain clinical settings such as type of causative organism or etiology. These studies should include outcomes that take patients' symptoms and clinical examination into account; report outcomes in a uniform and consistent manner; and follow up at short- and long-term intervals.

摘要

背景

眼内炎是指涉及房水或玻璃体或两者的严重眼部感染,并且会威胁视力。大多数眼内炎是外源性的(即由于来自外部来源的生物体接种),大多数外源性眼内炎是急性的,发生在眼内手术后。治疗的主要方法是紧急给予广谱玻璃体内抗生素。由于其抗炎作用,皮质类固醇与抗生素联合使用被认为对眼内炎的治疗有益。

目的

评估抗生素联合皮质类固醇与单独使用抗生素治疗眼内手术后或玻璃体内注射后发生的急性眼内炎的疗效。

检索方法

我们检索了 Cochrane 中心对照试验注册库(CENTRAL)(包含 Cochrane 眼部与视觉试验注册库)(2021 年,第 8 期)、MEDLINE Ovid(1946 年至 2021 年 8 月)、Embase Ovid(1980 年至 2021 年 8 月)、LILACS(拉丁美洲和加勒比健康科学文献数据库)(1982 年至 2021 年 8 月)、ISRCTN 注册库;2021 年 8 月检索 ClinicalTrials.gov;2021 年 8 月检索世界卫生组织国际临床试验注册平台。我们在检索试验时没有对电子检索设置任何日期或语言限制。

选择标准

我们纳入了比较在眼内手术后或玻璃体内注射后治疗急性、临床诊断的眼内炎时,辅助皮质类固醇与单独使用抗生素的有效性的随机对照试验(RCT)。我们排除了参与者患有内源性眼内炎的试验,除非按感染来源报告了结局。我们对抗生素和皮质类固醇的使用方法或顺序、剂量、频率和持续时间没有限制。

数据收集和分析

我们使用标准的 Cochrane 方法,使用 GRADE 分类法对六个结局的证据质量进行分级。

主要结果

我们在本次更新的综述中纳入了四项 RCT,共有 264 只眼的 264 名参与者。这些研究在南非、印度和荷兰进行。所有研究均使用玻璃体内地塞米松作为辅助皮质类固醇治疗,并使用两种玻璃体内抗生素联合治疗,为抗生素治疗提供革兰阳性和革兰阴性覆盖。我们判断两项研究总体上具有低偏倚风险,而另外两项研究由于缺乏对研究方法的报告,总体上具有不确定的偏倚风险。只有一项研究在临床试验注册库中进行了注册。虽然纳入的研究均未报告我们方案中定义的眼内炎完全消退的主要结局,但一项研究报告了联合解剖学和功能成功率(即具有至少 5mmHg 眼内压和至少 6/120 视力的参与者比例)。非常低确定性证据表明,在比较辅助皮质类固醇与单独使用抗生素时,联合成功率没有差异(风险比 (RR) 1.08,95%置信区间 (CI) 0.80 至 1.45;32 名参与者)。两项研究的低确定性证据表明,与单独使用抗生素相比,辅助地塞米松可能在 3 个月时导致良好的视力结局(Snellen 视力 6/6 至 6/18)(RR 1.95,95%CI 1.05 至 3.60;60 名参与者);然而,在 12 个月时证据不太确定(RR 1.12,95%CI 0.92 至 1.37;2 项研究;195 名参与者;低确定性证据)。一项研究的研究者报告了视力的改善,但我们无法评估辅助皮质类固醇治疗的效果,因为研究研究者没有提供任何精度估计。只有一项研究检查了眼内压(IOP)。证据表明,辅助地塞米松治疗可能会在干预 12 个月后略微降低 IOP(平均差值-1.90,95%CI -3.78 至 0.07;1 项研究;167 名参与者;低确定性证据)。三项研究报告了不良事件(视网膜脱离、低眼压、增生性玻璃体视网膜病变、瞳孔分离、飞蚊症和缩窄)。使用地塞米松的患者中有 14 例(12.6%)发生了任何不良事件,而未使用地塞米松的患者中有 12 例(10.3%)发生了不良事件。我们只能对视网膜脱离的发生进行汇总分析:两组之间的任何差异都不确定(RR 1.41,95%CI 0.53 至 3.74;227 名参与者;低确定性证据)。没有研究报告成本相关结局。

作者结论

目前关于眼内手术后急性眼内炎治疗中辅助皮质类固醇治疗与单独使用抗生素的有效性的证据不足。我们没有发现纳入眼内注射后急性眼内炎病例的研究。两项研究的联合分析表明,与不使用辅助皮质类固醇相比,使用辅助皮质类固醇可能在三个月时更有可能获得良好的视力结局。然而,考虑到大多数置信区间都跨越了零值,而且本综述在范围和适用性方面都受到限制,目前还不能得出使用辅助皮质类固醇是否有效的结论。任何未来的试验都应该研究辅助皮质类固醇在某些临床环境(如病因病原体或病因类型)中是否有用。这些研究应该考虑到患者的症状和临床检查;以统一和一致的方式报告结局;并在短期和长期随访。

相似文献

1
Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure.眼内手术后急性眼内炎中辅助性皮质类固醇治疗与单独使用抗生素的比较。
Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD012131. doi: 10.1002/14651858.CD012131.pub3.
2
Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure.辅助性类固醇疗法与单纯抗生素疗法治疗眼内手术后急性眼内炎的对比
Cochrane Database Syst Rev. 2017 Feb 22;2(2):CD012131. doi: 10.1002/14651858.CD012131.pub2.
3
Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis. topical 药物干预与安慰剂治疗流行性角膜结膜炎的疗效比较。
Cochrane Database Syst Rev. 2022 Mar 3;3(3):CD013520. doi: 10.1002/14651858.CD013520.pub2.
4
Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.抗血管内皮生长因子联合玻璃体内注射类固醇治疗糖尿病性黄斑水肿。
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD011599. doi: 10.1002/14651858.CD011599.pub2.
5
Surgical interventions for bilateral congenital cataract in children aged two years and under.儿童两岁及以下双侧先天性白内障的手术干预。
Cochrane Database Syst Rev. 2022 Sep 15;9(9):CD003171. doi: 10.1002/14651858.CD003171.pub3.
6
Non-steroidal anti-inflammatory agents for treating cystoid macular edema following cataract surgery.非甾体类抗炎药治疗白内障术后囊样黄斑水肿。
Cochrane Database Syst Rev. 2022 Dec 15;12(12):CD004239. doi: 10.1002/14651858.CD004239.pub4.
7
Topical corticosteroids for dry eye.局部皮质类固醇治疗干眼。
Cochrane Database Syst Rev. 2022 Oct 21;10(10):CD015070. doi: 10.1002/14651858.CD015070.pub2.
8
Cyclodestructive procedures for non-refractory glaucoma.非难治性青光眼的睫状体破坏手术
Cochrane Database Syst Rev. 2018 Apr 25;4(4):CD009313. doi: 10.1002/14651858.CD009313.pub2.
9
Immediate sequential bilateral surgery versus delayed sequential bilateral surgery for cataracts.即刻序双侧白内障手术与延迟序双侧白内障手术比较。
Cochrane Database Syst Rev. 2022 Apr 25;4(4):CD013270. doi: 10.1002/14651858.CD013270.pub2.
10
Aural toilet (ear cleaning) for chronic suppurative otitis media.慢性化脓性中耳炎的耳道清理(耳部清洁)
Cochrane Database Syst Rev. 2025 Jun 9;6(6):CD013057. doi: 10.1002/14651858.CD013057.pub3.

引用本文的文献

1
Seeing the unseen: The low treatment rate of eye emergencies in Africa.洞察不可见之事:非洲眼部急症的低治疗率
World J Methodol. 2025 Sep 20;15(3):102477. doi: 10.5662/wjm.v15.i3.102477.
2
Controversies in the management of endophthalmitis: a 5-year retrospective cohort study.眼内炎治疗中的争议:一项为期5年的回顾性队列研究。
J Ophthalmic Inflamm Infect. 2025 Mar 17;15(1):28. doi: 10.1186/s12348-025-00468-8.
3
Economic evaluation of an adjunctive intraocular and peri-ocular steroid vitreoretinal surgery for open globe trauma: Cost-effectiveness of the ASCOT randomised controlled trial.开放性眼球外伤辅助性眼内及眼周类固醇玻璃体视网膜手术的经济学评估:ASCOT随机对照试验的成本效益分析
PLoS One. 2024 Dec 16;19(12):e0311158. doi: 10.1371/journal.pone.0311158. eCollection 2024.
4
Management and Prognosis of Acute Post-Cataract Surgery Endophthalmitis: A 10-Year Retrospective Analysis in Eastern China.急性白内障手术后眼内炎的管理与预后:中国东部地区的10年回顾性分析
Antibiotics (Basel). 2023 Nov 28;12(12):1670. doi: 10.3390/antibiotics12121670.
5
The Role of Adjuvant Systemic and Intravitreal Corticosteroids in Fungal Endophthalmitis Treatment.辅助性全身及玻璃体内皮质类固醇在真菌性眼内炎治疗中的作用
J Fungi (Basel). 2023 Nov 28;9(12):1147. doi: 10.3390/jof9121147.
6
Gram-Negative Endogenous Endophthalmitis: A Systematic Review.革兰氏阴性内源性眼内炎:一项系统评价。
Microorganisms. 2022 Dec 28;11(1):80. doi: 10.3390/microorganisms11010080.

本文引用的文献

1
Post-surgical management of cataract: Light and dark in the 2020s.白内障术后管理:21 世纪的光明与黑暗。
Eur J Ophthalmol. 2021 Mar;31(2):287-290. doi: 10.1177/1120672120963458. Epub 2020 Oct 20.
2
Clinical Decision Making and Visual Outcomes in Endophthalmitis Treated with Systemic Corticosteroids.临床决策与眼内炎全身应用皮质类固醇治疗的视觉结局。
Ophthalmol Retina. 2020 Nov;4(11):1103-1108. doi: 10.1016/j.oret.2020.04.026. Epub 2020 May 5.
3
One week of levofloxacin plus dexamethasone eye drops for cataract surgery: an innovative and rational therapeutic strategy.白内障手术中左氧氟沙星联合地塞米松滴眼液一周治疗:一种创新且合理的治疗策略。
Eye (Lond). 2020 Nov;34(11):2112-2122. doi: 10.1038/s41433-020-0869-1. Epub 2020 May 4.
4
International Practice Patterns for the Management of Acute Postsurgical and Postintravitreal Injection Endophthalmitis: European Vitreo-Retinal Society Endophthalmitis Study Report 1.急性手术后及玻璃体内注射后眼内炎管理的国际实践模式:欧洲玻璃体视网膜学会眼内炎研究报告1
Ophthalmol Retina. 2019 Jun;3(6):461-467. doi: 10.1016/j.oret.2019.03.009. Epub 2019 Mar 21.
5
Endophthalmitis after intravitreal triamcinolone-moxifloxacin.玻璃体内注射曲安奈德-莫西沙星后的眼内炎
J Cataract Refract Surg. 2019 May;45(5):705-706. doi: 10.1016/j.jcrs.2019.01.037.
6
Topical levofloxacin, nepafenac and prednisolone acetate medication after cataract surgery in the biggest tertiary eye hospital in Finland during 2015-2018.2015年至2018年期间,芬兰最大的三级眼科医院白内障手术后使用局部左氧氟沙星、奈帕芬酸和醋酸泼尼松龙的情况。
Acta Ophthalmol. 2019 Sep;97(6):e943-e945. doi: 10.1111/aos.14091. Epub 2019 Mar 27.
7
A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics.一项关于疑似白内障手术后细菌性眼内炎患者辅助使用玻璃体内地塞米松与玻璃体内抗生素的前瞻性多中心随机安慰剂对照优效性试验。
Acta Ophthalmol. 2018 Jun;96(4):348-355. doi: 10.1111/aos.13610. Epub 2017 Dec 7.
8
Postoperative Endophthalmitis: A Review of Risk Factors, Prophylaxis, Incidence, Microbiology, Treatment, and Outcomes.术后眼内炎:危险因素、预防、发病率、微生物学、治疗及预后的综述
Semin Ophthalmol. 2018;33(1):95-101. doi: 10.1080/08820538.2017.1353826. Epub 2017 Nov 27.
9
Aqueous humor concentrations of topical fluoroquinolones alone or in combination with a steroid.单独使用或与类固醇联合使用的局部氟喹诺酮类药物的房水浓度。
Arq Bras Oftalmol. 2017 Sep-Oct;80(5):300-303. doi: 10.5935/0004-2749.20170073.
10
Aqueous Humor Penetration and Biological Activity of Moxifloxacin 0.5% Ophthalmic Solution Alone or with Dexamethasone 0.1.莫西沙星 0.5%滴眼液单独使用或与地塞米松 0.1%联合使用时房水穿透率和生物学活性
J Ocul Pharmacol Ther. 2017 Mar;33(2):98-102. doi: 10.1089/jop.2016.0126.